β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease

Autor: Doo Soon Im, Xianjun Dong, Patrizia Rizzu, Ming Jin, Yang Kevin Xiang, Peter Heutink, Trond Riise, Birgitt Schüle, Elizabeth Long, Marcie A. Glicksman, Dennis J. Selkoe, Clemens R. Scherzer, Bing Xu, Tim Bartels, Kristine M. Abo, Jean-Christophe Rochet, Barbara J. Caldarone, Joseph J. Locascio, Shuchi Mittal, David S. Park, Adrian Flierl, Anders Engeland, Vikram Khurana, Kjetil Bjornevik
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Parkinson's disease
metabolism [Histones]
Transcription
Genetic
genetics [Receptors
Adrenergic
beta-2]
Regulator
pharmacology [Propranolol]
drug effects [Gene Expression Regulation]
Bioinformatics
Ligands
Histones
chemistry.chemical_compound
Mice
0302 clinical medicine
pharmacology [Adrenergic beta-1 Receptor Agonists]
genetics [Parkinson Disease]
metabolism [Receptors
Adrenergic
beta-2]
Promoter Regions
Genetic
therapeutic use [Propranolol]
Regulation of gene expression
Multidisciplinary
biology
Norway
Parkinson Disease
Acetylation
Propranolol
Substantia Nigra
Histone
Enhancer Elements
Genetic
Neuroprotective Agents
Adrenergic beta-1 Receptor Agonists
pharmacology [Albuterol]
genetics [alpha-Synuclein]
alpha-Synuclein
drug effects [Transcription
Genetic]
Agonist
Risk
medicine.drug_class
Adrenergic beta-Antagonists
pharmacology [Adrenergic beta-Antagonists]
therapeutic use [Adrenergic beta-Antagonists]
Article
03 medical and health sciences
Cell Line
Tumor
medicine
metabolism [Substantia Nigra]
Animals
Humans
Albuterol
ethnology [Norway]
SNCA protein
human
Enhancer
Gene
Alpha-synuclein
pharmacology [Neuroprotective Agents]
medicine.disease
drug therapy [Parkinson Disease]
030104 developmental biology
Gene Expression Regulation
chemistry
ddc:320
biology.protein
Cancer research
Receptors
Adrenergic
beta-2
030217 neurology & neurosurgery
therapeutic use [Albuterol]
ethnology [Parkinson Disease]
Zdroj: Science / Science now 357(6354), 891-898 (2017). doi:10.1126/science.aaf3934
Popis: Elucidating the risk of Parkinson's disease High expression of the α-synuclein gene ( SNCA ) is a risk factor for Parkinson's disease (PD), but certain drugs may mitigate this risk. Mittal et al. ran a small-molecule screen to identify compounds that regulate levels of SNCA expression and found that several β2-adrenoreceptor (β2AR) agonists reduced them (see the Perspective by Snyder). These compounds modulated epigenetic marks at the SNCA gene, effectively suppressing SNCA transcription. The authors looked at the pharmaceutical history of more than 4 million Norwegians over an 11-year period and found a reduced risk of PD among those that were taking one of the β2AR agonists for other medical problems. Science , this issue p. 891 ; see also p. 869
Databáze: OpenAIRE
Externí odkaz: